[go: up one dir, main page]

WO2008079326A3 - Methods for using and identifying modulators of delta-like 4 - Google Patents

Methods for using and identifying modulators of delta-like 4 Download PDF

Info

Publication number
WO2008079326A3
WO2008079326A3 PCT/US2007/026149 US2007026149W WO2008079326A3 WO 2008079326 A3 WO2008079326 A3 WO 2008079326A3 US 2007026149 W US2007026149 W US 2007026149W WO 2008079326 A3 WO2008079326 A3 WO 2008079326A3
Authority
WO
WIPO (PCT)
Prior art keywords
delta
methods
identifying modulators
identifying
modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/026149
Other languages
French (fr)
Other versions
WO2008079326A2 (en
Inventor
Parkash Gill
Ren Liu
Valery Krasnoperov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vasgene Therapeutics Inc
Original Assignee
Vasgene Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasgene Therapeutics Inc filed Critical Vasgene Therapeutics Inc
Priority to EP07853456A priority Critical patent/EP2120996A2/en
Priority to AU2007338734A priority patent/AU2007338734A1/en
Publication of WO2008079326A2 publication Critical patent/WO2008079326A2/en
Publication of WO2008079326A3 publication Critical patent/WO2008079326A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

In certain embodiments, this present invention provides methods of identifying and using agonists and antagonists of Delta-like 4 (D114) signaling for the treatment of tumours.
PCT/US2007/026149 2006-12-20 2007-12-20 Methods for using and identifying modulators of delta-like 4 Ceased WO2008079326A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP07853456A EP2120996A2 (en) 2006-12-20 2007-12-20 Methods for using and identifying modulators of delta-like 4
AU2007338734A AU2007338734A1 (en) 2006-12-20 2007-12-20 Methods for using and identifying modulators of delta-like 4

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87644406P 2006-12-20 2006-12-20
US60/876,444 2006-12-20
US90175407P 2007-02-16 2007-02-16
US60/901,754 2007-02-16

Publications (2)

Publication Number Publication Date
WO2008079326A2 WO2008079326A2 (en) 2008-07-03
WO2008079326A3 true WO2008079326A3 (en) 2008-10-30

Family

ID=39311083

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/026149 Ceased WO2008079326A2 (en) 2006-12-20 2007-12-20 Methods for using and identifying modulators of delta-like 4

Country Status (3)

Country Link
EP (1) EP2120996A2 (en)
AU (1) AU2007338734A1 (en)
WO (1) WO2008079326A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906116B2 (en) * 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
SI2066694T1 (en) 2006-09-29 2016-02-29 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
EP2899209A1 (en) 2008-04-29 2015-07-29 Abbvie Inc. Dual Variable Domain Immunoglobulins and uses thereof
EP2297208A4 (en) 2008-06-03 2012-07-11 Abbott Lab Dual variable domain immunoglobulins and uses thereof
BRPI0913406A2 (en) 2008-06-03 2018-01-09 Abbott Lab double variable domain immunoglobulins and their uses
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
CA2729306C (en) 2008-07-08 2015-08-18 Oncomed Pharmaceuticals, Inc. Notch-binding agents and antagonists and methods of use thereof
US8834875B2 (en) 2010-01-13 2014-09-16 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
RU2012112550A (en) 2009-09-01 2013-10-10 Эбботт Лэборетриз IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND THEIR APPLICATION
US8716450B2 (en) 2009-10-15 2014-05-06 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
TR201818814T4 (en) 2009-10-16 2019-01-21 Oncomed Pharm Inc Therapeutic combination and use of Dll4 antagonist antibodies and anti-hypertensive agents.
UY32979A (en) 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
TWI535445B (en) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt antagonists and methods of treatment and screening
TW201206473A (en) 2010-08-03 2012-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
PE20140229A1 (en) 2010-08-26 2014-03-27 Abbvie Inc IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
PT3485903T (en) 2011-09-23 2023-02-17 Mereo Biopharma 5 Inc Vegf/dll4 binding agents and uses thereof
TW201333035A (en) 2011-12-30 2013-08-16 Abbvie Inc Dual specific binding proteins directed against IL-13 and/or IL-17
UY35110A (en) 2012-11-01 2014-05-30 Abbvie Inc ANTI-VEGF / DLL4 DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES OF THE SAME
CA2904448A1 (en) 2013-03-15 2014-09-18 Tariq Ghayur Dual specific binding proteins directed against il-1.beta. and/or il-17
ES2808153T3 (en) 2014-10-31 2021-02-25 Mereo Biopharma 5 Inc Combination therapy for disease treatment
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
AU2016326609B2 (en) 2015-09-23 2023-03-09 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1004669A1 (en) * 1997-05-14 2000-05-31 Asahi Kasei Kogyo Kabushiki Kaisha Novel differentiation inhibitor
WO2007070671A2 (en) * 2005-12-16 2007-06-21 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with dll4 antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1004669A1 (en) * 1997-05-14 2000-05-31 Asahi Kasei Kogyo Kabushiki Kaisha Novel differentiation inhibitor
WO2007070671A2 (en) * 2005-12-16 2007-06-21 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with dll4 antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NOGUERA-TROISE IRENE ET AL: "Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis.", NATURE 21 DEC 2006, vol. 444, no. 7122, 21 December 2006 (2006-12-21), pages 1032 - 1037, XP002489427, ISSN: 1476-4687 *
RIDGWAY JOHN ET AL: "Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis.", NATURE 21 DEC 2006, vol. 444, no. 7122, 21 December 2006 (2006-12-21), pages 1083 - 1087, XP002489428, ISSN: 1476-4687 *

Also Published As

Publication number Publication date
EP2120996A2 (en) 2009-11-25
AU2007338734A1 (en) 2008-07-03
WO2008079326A2 (en) 2008-07-03

Similar Documents

Publication Publication Date Title
WO2008079326A3 (en) Methods for using and identifying modulators of delta-like 4
WO2009085209A3 (en) Methods for using and identifying modulators of delta-like 4
WO2007028110A3 (en) Methods for using and identifying modulators of delta-like 4
WO2008033408A3 (en) Methods for identifying compounds that modulate cell signaling and methods employing such compounds
TW200732349A (en) Anti-OX40L antibodies and methods using same
WO2007081740A3 (en) Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers
MX2009012625A (en) Methods of treating, diagnosing and detecting fgf21-associated disorders.
MX2008001652A (en) Polyammonium/polysiloxane copolymers.
MX2009008430A (en) Anti-robo4 antibodies and uses therefor.
WO2007136893A3 (en) Anti-fgf19 antibodies and methods using same
WO2009009173A3 (en) Klotho-beta for use in treating cancer, liver disorders, gallstones, wasting syndrome and obesity-related diseases
WO2007056681A3 (en) Methods for administering hypoglycemic agents
MX2010004374A (en) Protein scaffolds.
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
WO2009044173A3 (en) Methods of treating cancer using notch pathway inhibitors
MX2009013082A (en) C3b antibodies and methods for the prevention and treatment of complement- associated disorders.
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
TN2009000181A1 (en) Agonist trkb antibodies and uses thereof
MX2010006206A (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases.
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
TW200833842A (en) Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
MX2007010560A (en) Roflumilast for the treatment of diabetes mellitus.
MX2009006812A (en) Modulators of c3a receptor and methods of use thereof.
WO2007076174A3 (en) Methods, systems, and apparatus for multi-domain markers
SG161281A1 (en) Hgf beta chain variants

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07853456

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007338734

Country of ref document: AU

Ref document number: 2007853456

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007338734

Country of ref document: AU

Date of ref document: 20071220

Kind code of ref document: A